Cytosorbents Corporation

Bewertungs-Analyse

Über das Unternehmen

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, to

Trading-Daten

Ähnliche Aktien aus dem Sektor

Wo kann ich Cytosorbents Corporation kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.